Business Context and Reporting Period
This Form 6-K filing by Sanofi-Aventis covers the month of May 2006, specifically dated May 9, 2006. The report serves to disclose a material corporate event rather than providing periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notification of a specific product launch and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is the commercial launch of the antiplatelet drug PLAVIX (clopidogrel) in Japan. This event expands the company's geographic footprint for this specific product line.
Guidance, Outlook, and Risks
The filing incorporates a press release regarding the PLAVIX launch in Japan. It does not contain updated financial guidance, management commentary on overall outlook, specific risk factors, or details on contingencies beyond the operational milestone of the product launch.
Investor Verification Checklist
- Verify the regulatory approval status and commercial terms for PLAVIX in the Japanese market.
- Assess the potential revenue contribution of the Japanese market to the global PLAVIX portfolio.
- Review subsequent quarterly reports for the financial impact of this launch.